Fresh Tracks Therapeutics, Inc.
FRTX · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.01 | 0.01 |
| FCF Yield | -21.62% | 53.74% | -43.84% | -180.89% |
| EV / EBITDA | 4.62 | -2.97 | 2.11 | 1.94 |
| Quality | ||||
| ROIC | -16.64% | 18.24% | -29.51% | -43.88% |
| Gross Margin | 0.00% | 100.00% | -1,049.06% | -21,411.11% |
| Cash Conversion Ratio | 0.91 | 1.46 | 0.80 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 170.61% | 213.30% | 97.55% | 105.28% |
| Free Cash Flow Growth | -136.47% | 269.71% | 59.51% | -73.97% |
| Safety | ||||
| Net Debt / EBITDA | 8.85 | -5.68 | 3.93 | 2.52 |
| Interest Coverage | 0.00 | 0.00 | -1,182.00 | -1,447.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.37 | 2.49 |
| Cash Conversion Cycle | 0.00 | 0.00 | 443.67 | 2,656.60 |